Nanoviricides Inc (NNVC)
1.13
-0.07
(-5.83%)
USD |
NYAM |
May 03, 16:00
1.13
0.00 (0.00%)
After-Hours: 20:00
Nanoviricides Research and Development Expense (Annual): 6.392M for June 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2023 | 6.392M |
| June 30, 2022 | 5.785M |
| June 30, 2021 | 6.114M |
| June 30, 2020 | 4.696M |
| June 30, 2019 | 5.922M |
| June 30, 2018 | 5.914M |
| June 30, 2017 | 6.566M |
| June 30, 2016 | 5.029M |
| June 30, 2015 | 3.660M |
| June 30, 2014 | 5.132M |
| Date | Value |
|---|---|
| June 30, 2013 | 4.293M |
| June 30, 2012 | 4.266M |
| June 30, 2011 | 4.156M |
| June 30, 2010 | 3.205M |
| June 30, 2009 | 1.734M |
| June 30, 2008 | 0.8392M |
| June 30, 2007 | 0.7318M |
| June 30, 2006 | 0.8999M |
| June 30, 2005 | 0.0308M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.696M
Minimum
2020
6.392M
Maximum
2023
5.782M
Average
5.922M
Median
2019
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |